S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
PHIO · Phio Pharmaceuticals Corp.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Phio Pharmaceuticals Corp (PHIO)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$0.92
+0.05
(+5.72%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$0.92
$0.92
$0.92
52-WEEK RANGE
$0.92
$0.81
$4.19
What's happening
- PHIO is up 5.72% today, trading at $0.92. — Live quote
- Volume today (100) is well below its 3-month average of 464,550. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 21 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.36 actual vs. $-0.37 estimated (+2.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 4
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PHIO
-15.04%
vs S&P 500
-27.82%
1-YEAR RETURN
PHIO
-58.70%
vs S&P 500
-73.26%
6-MONTH RETURN
PHIO
-29.76%
3-MONTH RETURN
PHIO
-21.05%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.36
Est. $-0.37
BEAT +2.0%
2026-04-26 (Q1 2026)
$-0.34
Est. $-0.24
MISS -41.8%
2026-01-26 (Q4 2025)
$-0.25
Est. $-0.35
BEAT +27.0%
2025-10-26 (Q3 2025)
$-0.44
Est. $-0.46
BEAT +4.1%
Valuation Measures & Ratios
Enterprise Value4-$2.8M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)73.14
Price / Book70.94
EV4 / Revenue-19.69
EV4 / EBITDA—
Profit Margin-3935.71%
Operating Margin-3957.14%
Return on Equity (ROE8)-87.41%
Return on Assets (ROA9)-79.76%
Avg Volume (3M)464,550
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | — | — | — | $11.3M | $5.5M |
| P/E | — | — | — | -1.54 | -0.75 |
| Price/Book | — | — | — | 1.12 | 0.45 |
| ROE | — | — | — | -72.36% | -59.93% |
| ROA | — | — | — | -64.64% | -54.26% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short89,454
Change from Prior Settlement-40.32%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -3935.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -58.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PHIO
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$4.3M | -$4.2M | -$2.5M | -$2.3M | -$1.9M | -$1.6M | -$1.9M | -$2.2M |
| Net income | -$4.1M | -$4.0M | -$2.4M | -$2.2M | -$1.8M | -$1.5M | -$1.8M | -$2.2M |
| EPS (diluted) | — | — | — | $-0.45 | $-0.41 | $-1.54 | $-3.62 | $-0.47 |
| EPS (basic) | $-0.36 | $-0.34 | $-0.44 | $-0.45 | $-0.41 | $-1.54 | $-3.62 | $-0.47 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $14.3M | $17.4M | $21.5M | $11.5M | $11.3M | $13.4M | $5.7M | $5.9M |
| Total liabilities | $1.7M | $950.0K | $1.3M | $1.7M | $1.2M | $1.3M | $1.0M | — |
| Stockholders' equity | $12.6M | $16.5M | $20.1M | $9.8M | $10.1M | $12.2M | $4.7M | $4.9M |
| Total current assets | $14.3M | $17.4M | $21.5M | $11.5M | $11.3M | $13.4M | $5.7M | $5.9M |
| Total current liabilities | — | — | — | — | $1.2M | $1.3M | $1.0M | $919.0K |
| Cash & equivalents | $13.0M | $17.0M | $21.0M | $10.7M | $10.8M | $13.3M | $5.4M | $5.4M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $9.0K | $10.0K | $11.0K | $12.0K | $7.0K | $4.0K | $2.0K | $1.0K |
| Other non-current assets | — | — | — | — | — | — | $0 | $0 |
| Accounts payable | $901.0K | $260.0K | $435.0K | $516.0K | $235.0K | $427.0K | $253.0K | $184.0K |
| Accrued liabilities | $804.0K | $690.0K | $905.0K | $1.1M | $971.0K | $843.0K | $762.0K | $735.0K |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $1.0K | $1.0K | $1.0K | $1.0K | $0 | $0 | $0 | $0 |
| Retained earnings | -$163.2M | -$159.1M | -$155.1M | -$152.7M | -$150.3M | -$148.1M | -$146.4M | -$144.7M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.0M | -$4.0M | -$2.1M | -$2.1M | -$2.5M | -$1.3M | -$1.4M | -$2.0M |
| Investing cash flow | $0 | $3.0K | $0 | -$7.0K | -$3.0K | -$2.0K | $8.0K | $0 |
| Financing cash flow | $0 | $0 | $12.4M | $2.0M | $40.0K | $9.2M | $1.4M | $2.6M |
| Free cash flow | -$4.0M | -$4.0M | -$2.1M | -$2.1M | -$2.5M | -$1.3M | -$1.4M | -$2.0M |
| Capital expenditures | $0 | $0 | $0 | $7.0K | $3.0K | $2.0K | $1.0K | $0 |
| Depreciation & amortization | $1.0K | $1.0K | $1.0K | $2.0K | $0 | $0 | $0 | $0 |
| Share-based compensation | $278.0K | $318.0K | $274.0K | $113.0K | $51.0K | $43.0K | $48.0K | $67.0K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts payable | $641.0K | -$175.0K | -$80.0K | $281.0K | -$192.0K | $174.0K | $69.0K | -$151.0K |
| Other investing activities | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | $0 | $30.0K | $0 | $0 | $1.0K | $0 |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | -$9.2M | -$7.4M | -$10.8M | -$11.5M | -$13.5M |
| Net income | -$8.7M | -$7.2M | -$10.8M | -$11.5M | -$13.3M |
| EPS (diluted) | — | $-9.08 | $-46.76 | $-10.10 | $-12.43 |
| EPS (basic) | $-1.45 | $-9.08 | $-46.76 | $-10.10 | $-12.43 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $21.5M | $5.7M | $9.4M | $12.8M | $25.2M |
| Total liabilities | $1.3M | $1.0M | $1.6M | $2.0M | $3.2M |
| Stockholders' equity | $20.1M | $4.7M | $7.7M | $10.8M | $21.9M |
| Total current assets | $21.5M | $5.7M | $9.3M | $12.4M | $24.7M |
| Total current liabilities | — | $1.0M | $1.6M | $1.9M | $3.1M |
| Cash & equivalents | $21.0M | $5.4M | $8.5M | — | — |
| Marketable securities (current) | — | — | — | — | — |
| Property, plant & equipment | $11.0K | $2.0K | $6.0K | $183.0K | $133.0K |
| Other non-current assets | — | $0 | $3.0K | $24.0K | $27.0K |
| Accounts payable | $435.0K | $253.0K | $657.0K | $779.0K | $283.0K |
| Accrued liabilities | $905.0K | $762.0K | $942.0K | $1.0M | $2.7M |
| Deferred revenue (current) | — | — | — | — | — |
| Long-term debt | — | — | — | — | $0 |
| Common stock & paid-in capital | $1.0K | $0 | $0 | $0 | $0 |
| Retained earnings | -$155.1M | -$146.4M | -$139.2M | -$128.4M | -$116.9M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$8.0M | -$7.1M | -$10.7M | -$12.1M | -$11.9M |
| Investing cash flow | -$12.0K | $8.0K | -$5.0K | -$121.0K | -$51.0K |
| Financing cash flow | $23.6M | $4.0M | $7.4M | -$26.0K | $21.7M |
| Free cash flow | -$8.0M | -$7.1M | -$10.8M | -$12.2M | -$11.9M |
| Capital expenditures | $12.0K | $1.0K | $5.0K | $121.0K | $51.0K |
| Depreciation & amortization | $3.0K | $2.0K | $56.0K | $71.0K | $75.0K |
| Share-based compensation | $481.0K | $147.0K | $303.0K | $414.0K | $480.0K |
| Deferred income taxes | — | — | — | — | — |
| Change in accounts payable | $183.0K | -$404.0K | -$122.0K | $496.0K | -$445.0K |
| Other investing activities | — | — | — | — | — |
| Tax withholding on stock comp | $30.0K | $5.0K | $26.0K | $28.0K | $1.0K |
| Other financing activities | — | — | — | — | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PHIO as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-09-11 to 2026-09-29
Recent transactions
- Insiders have net bought 65,500 shares over the last 182 days, across 8 purchases and 0 sales.
- Most recent: Plott Ronald Todd (Director) — Open market purchase of 5,000 shares on 2026-09-29.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)65,500 sh(8 txns)
Sales (open market)0 sh(0 txns)
Net Shares+65,500
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Plott Ronald Todd | Director | Open market purchase | 2026-09-29 | 5,000 |
| Carson Lisa Cabott | Chief Financial Officer | Grant / award | 2026-09-28 | 108,000 |
| Bitterman Robert J | Chairman, Pres. & CEO | Grant / award | 2026-09-28 | 400,000 |
| BRADFORD PATRICIA A | Director | Open market purchase | 2026-09-24 | 6,500 |
| Lockshin Curtis | Director | Grant / award | 2026-02-05 | 16,600 |
| Freeman Jonathan E | Director | Grant / award | 2026-02-05 | 16,600 |
| Deming David H | Director | Grant / award | 2026-02-05 | 23,800 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Plott Ronald Todd | Director | Open market purchase | 5,000 | $1.04 |
| 2026-09-28 | Plott Ronald Todd | Director | Open market purchase | 5,000 | $1.03 |
| 2026-09-28 | Carson Lisa Cabott | Chief Financial Officer | Grant / award | 108,000 | $0.00 |
| 2026-09-28 | Bitterman Robert J | Chairman, Pres. & CEO | Grant / award | 400,000 | $0.00 |
| 2026-09-28 | Plott Ronald Todd | Director | Grant / award | 17,000 | $0.00 |
| 2026-09-24 | BRADFORD PATRICIA A | Director | Open market purchase | 6,500 | $1.01 |
| 2026-09-22 | Bitterman Robert J | Chairman, Pres. & CEO | Open market purchase | 2,000 | $1.03 |
| 2026-09-15 | BRADFORD PATRICIA A | Director | Open market purchase | 12,000 | $1.03 |
| 2026-09-11 | Carson Lisa Cabott | Chief Financial Officer | Tax withholding | 12,888 | $1.03 |
| 2026-09-11 | Bitterman Robert J | Chairman, Pres. & CEO | Tax withholding | 68,550 | $1.03 |
| 2026-08-19 | Plott Ronald Todd | Director | Open market purchase | 15,000 | $1.14 |
| 2026-08-18 | Bitterman Robert J | Chairman, Pres. & CEO | Open market purchase | 10,000 | $1.06 |
| 2026-06-26 | Bitterman Robert J | Chairman, Pres. & CEO | Open market purchase | 10,000 | $0.99 |
| 2026-02-05 | Lockshin Curtis | Director | Grant / award | 16,600 | $0.00 |
| 2026-02-05 | Freeman Jonathan E | Director | Grant / award | 16,600 | $0.00 |
| 2026-02-05 | Deming David H | Director | Grant / award | 23,800 | $0.00 |
| 2026-02-05 | Carson Lisa Cabott | Chief Financial Officer | Grant / award | 47,000 | $0.00 |
| 2026-02-05 | BRADFORD PATRICIA A | Director | Grant / award | 18,500 | $0.00 |
| 2026-02-05 | Bitterman Robert J | Chairman, Pres. & CEO | Grant / award | 120,000 | $0.00 |
| 2025-12-31 | Bitterman Robert J | Chairman, Pres. & CEO | Open market purchase | 5,000 | $1.03 |
| 2025-12-23 | Bitterman Robert J | Chairman, Pres. & CEO | Open market purchase | 5,000 | $1.02 |
| 2025-11-21 | Bitterman Robert J | Chairman, Pres. & CEO | Open market purchase | 5,000 | $1.14 |
| 2025-11-18 | Bitterman Robert J | Chairman, Pres. & CEO | Open market purchase | 5,000 | $1.27 |
| 2025-09-11 | Deming David H | Director | Grant / award | 14,000 | $0.00 |
| 2025-09-11 | Lockshin Curtis | Director | Grant / award | 16,200 | $0.00 |
| 2025-09-11 | Freeman Jonathan E | Director | Grant / award | 14,700 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:44 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 8-K | 2026-10-13 | View on SEC.gov → |
| 2026-09-30 | 4 | 2026-09-28 | View on SEC.gov → |
| 2026-09-29 | 4 | 2026-09-28 | View on SEC.gov → |
| 2026-09-29 | 4 | 2026-09-28 | View on SEC.gov → |
| 2026-09-29 | 4 | 2026-09-28 | View on SEC.gov → |
| 2026-09-28 | 8-K | 2026-09-28 | View on SEC.gov → |
| 2026-09-25 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-23 | 4 | 2026-09-22 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-09-15 | 4 | 2026-09-11 | View on SEC.gov → |
| 2026-09-15 | 4 | 2026-09-11 | View on SEC.gov → |
| 2026-09-14 | 8-K | 2026-09-14 | View on SEC.gov → |
Recent news
Headlines about PHIO (Phio Pharmaceuticals Corp.). Links open the publisher — we don’t host full articles.
-
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Yahoo · 2026-10-19 -
ANGX,CDNL,CC,IDAI,AMRC,NTHI,PRTS,LIEN,DFH,RGCO,SELF,TISI,AIAI,EQPT,REFI,GROV,BRID,RVSB,AFCG,SRTS,BGDE,WVVI,PHIO,GME | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-19 -
CDNL,ANGX,CC,IDAI,NTHI,AMRC,PRTS,LIEN,DFH,RGCO,SELF,TISI,AIAI,EQPT,REFI,MTDR,GROV,BRID,RVSB,AFCG,SRTS,BGDE,PHIO,GME | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-17 -
CDNL,ANGX,CC,IDAI,NTHI,AMRC,PRTS,LIEN,DFH,RGCO,SELF,TISI,AIAI,REFI,EQPT,GROV,BRID,RVSB,AFCG,SRTS,BGDE,WVVI,PHIO,GME | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-17 -
CC,ANGX,CDNL,IDAI,AMRC,NTHI,PRTS,LIEN,DFH,RGCO,SELF,TISI,AIAI,EQPT,REFI,GROV,BRID,RVSB,AFCG,SRTS,BGDE,WVVI,PHIO,GME | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-16 -
CC,ANGX,CDNL,IDAI,NTHI,AMRC,PRTS,LIEN,RGCO,DFH,SELF,TISI,AIAI,EQPT,REFI,GROV,BRID,RVSB,AFCG,SRTS,BGDE,WVVI,PHIO,GME | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-16 -
CDNL,ANGX,CC,IDAI,AMRC,NTHI,CUEN,PRTS,LIEN,DFH,RGCO,SELF,TISI,REFI,EQPT,MTDR,GROV,BRID,RVSB,AFCG,SRTS,BGDE,PHIO,GME | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-15 -
ANGX,CDNL,CC,IDAI,AMRC,NTHI,PRTS,LIEN,DFH,RGCO,SELF,TISI,AIAI,REFI,EQPT,MTDR,GROV,BRID,RVSB,AFCG,SRTS,BGDE,PHIO,GME | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-15
No headlines in this category right now — try “All”.